Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 84

Sort by

Sort Order Select

Journal Articles

Combined Modality Low-Dose Radiation Therapy (2 Gy x 2) and Single-Agent Rituximab Immunotherapy in the Treatment of Indolent Non-Hodgkin Lymphoma

Samantha Brocklehurst, Neil Desai, MD MHS, Jennifer L Shah, MD, Syed Rizvi, MD, Praveen Ramakrishnan Geethakumari, MD, Kiran A Kumar, MD MBA

Blood (2019) 134 (Supplement_1): 5262.

https://doi.org/10.1182/blood-2019-131246

Published: 2019

Journal Articles

Primary Ocular Lymphoma: A SEER Database Analysis of Patterns of Involvement and Outcomes

Arushi Khurana, MBBS, Taha Al-Juhaishi, MD, Victor Yazbeck, MD, Danielle Shafer, DO

Blood (2019) 134 (Supplement_1): 4013.

https://doi.org/10.1182/blood-2019-132011

Published: 2019

Journal Articles

Omission of Staging Bone Marrow Biopsy Does Not Affect Outcomes in Patients with Stage I Extranodal Marginal Zone Lymphoma (EMZL) Treated with Radiation Therapy

Juan Pablo Alderuccio, MD, Derek Isrow, MD PhD, Isildinha M. Reis, PhD, Sunil Iyer, MD, Jessica Meshman, MD, Wei Zhao, MD MS, Arnold M. Markoe, MD, Izidore S. Lossos, MD

Blood (2019) 134 (Supplement_1): 2829.

https://doi.org/10.1182/blood-2019-124964

Published: 2019

Journal Articles

Non-Diffuse Large B-Cell Primary Central Nervous System Lymphoma

Sangeetha Gandhi, MBBS, Grzegorz S. Nowakowski, MD, Thomas M. Habermann, MD, Kay M. Ristow, BS, Patrick Johnston

Blood (2018) 132 (Supplement 1): 4208.

https://doi.org/10.1182/blood-2018-99-119741

Published: 2018

Journal Articles

Disease Characteristics and Treatment of Adult Langerhans Cell Histiocytosis: A Single Center Experience

Jason Signorelli, MD PhD MBA, Sowmya Ravulapati, MBBS, Jay L Patel, MD, Michael W. Deininger, MD PhD, Srinivas K. Tantravahi, MBBS

Blood (2018) 132 (Supplement 1): 4315.

https://doi.org/10.1182/blood-2018-99-120290

Published: 2018

Journal Articles

Genetic Landscape of Ocular Adnexa Extranodal Marginal Zone Lymphoma

Marco Magistri, PhD MS, Lanie Happ, Jeremy Ramdial, MD, Kranthi Kunkalla, Sander R Dubovy, MD, Jennifer R Chapman, MD, Francisco Vega, MD PhD, Sandeep Dave, MD, Izidore S. Lossos, MD

Blood (2018) 132 (Supplement 1): 923.

https://doi.org/10.1182/blood-2018-99-111325

Published: 2018

Journal Articles

Prophylaxis with Intrathecal Chemotherapy and High Dose Methotrexate in Patients with Diffuse Large B Cell Lymphoma at High Risk for Central Nervous System Relapse: A Single Centre Experience

Dario Marino, MD PhD, Silvia Finotto, MD, Caterina Boso, MD, Federica Vianello, MD, Benedetta Chiusole, MD, Marco Pizzi, MD, Paola Fogar, MD, Vittorina Zagonel, MD

Blood (2018) 132 (Supplement 1): 5420.

https://doi.org/10.1182/blood-2018-99-119164

Published: 2018

Journal Articles

Concomitant Use of Blinatumomab and Donor Lymphocyte Infusion for Post-Transplant Relapsed CD19 Positive Acute Lymphoblastic Leukemia: Systematic Review

Ceren Durer, MD, Seren Durer, MD, Madeeha Shafqat, Zunairah Shah, MBBS, Maryam Sadiq, MBBS, Muhammad Asad Fraz, MD, Malik Qistas Ahmad, MD MBBS, Hafiz Muhammad Fazeel, MD, Sharoon Samuel, MBBS, Mustafa Nadeem Malik, MD, Midhat Lakhani, MD, Chaudhry Saad Sohail, MD, Anum Qureshi, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 5742.

https://doi.org/10.1182/blood-2018-99-109998

Published: 2018

Journal Articles

Incidence and Risk Factors of Central Nervous System Relapse in Localized Extranodal NK/T-Cell Lymphoma, Nasal Type: An Analysis of Nkea Study

Kana Miyazaki, MD PhD, Senzo Taguchi, MD PhD, Masahiko Oguchi, MD PhD, Ritsuro Suzuki, MD PhD, Naoko Asano, MD PhD, Yasuhito Terui, MD PhD, Nobuko Kubota, MD PhD, Yoshihiro Saito, MD PhD, Takeshi Maeda, MD, Satoshi Itasaka, MD, Yukio Kobayashi, MD DSc, Jun Itami, MD PhD, Jun Amaki, MD PhD, Takeshi Akiba, MD PhD, Tohru Murayama, MD PhD, Noriko Ii, MD PhD, Toshinori Soejima, MD PhD, Motoko Yamaguchi, MD PhD, Naoyuki Katayama, MD PhD

Blood (2018) 132 (Supplement 1): 2935.

https://doi.org/10.1182/blood-2018-99-115546

Published: 2018

Journal Articles

Anaplastic Myeloma Arising from Myeloma: Successful Management of Two Diseases in an Individual

Cesar Rodriguez, MD, Roy Ervin Strowd III, MD, David D Grier

Blood (2017) 130 (Supplement 1): 5410.

https://doi.org/10.1182/blood.V130.Suppl_1.5410.5410

Published: 2017

Journal Articles

Efficacy of Radiation Treatement in Ocular Adnexa Mucosa-Associated Lymphoid Tissue Lymphoma: A Retrospective Evaluation in a Single Center Experience

Dario Marino, MDPhD, Maital Bolshinsky, MD, Silvia Finotto, MD, Raffaele Parrozzani, MD, Caterina Boso, MD, Federica Vianello, MD, Edoardo Midena, MD, Luca Canziani, MD, Laura Evangelista, MD, Vittorina Zagonel, MD

Blood (2017) 130 (Supplement 1): 2781.

https://doi.org/10.1182/blood.V130.Suppl_1.2781.2781

Published: 2017

Journal Articles

Rituximab-Bendamustine in First Line Treatment of Patients with Follicular Lymphoma. Results of Prospective Multicenter Study

Nesterova Ekaterina, MD PhD, Sergey K. Kravchenko, MD PhD, Alla M. Kovrigina, MD PhD, Lubov V. Plastinina, MD PhD, Yana K. Mangasarova, MD PhD, Liliya Gorenkova, PhD, Vladimir Vorobyev, MD PhD, Dmitriy Mariin, Elena A. Baryakh, MD PhD, Yuriy Polyakov, Pervin Zeynalova, MD PhD, Elena Volodicheva, MD, Nataliya Glonina, Valeriy G. Savchenko

Blood (2017) 130 (Supplement 1): 5170.

https://doi.org/10.1182/blood.V130.Suppl_1.5170.5170

Published: 2017

Journal Articles

Curative radiation for orbital MZL: how much?

Joachim Yahalom

Blood (2017) 129 (3): 270–271.

https://doi.org/10.1182/blood-2016-11-749176

Published: 2017

Journal Articles

Limited Role of Workup Including PET-CT, Esophagogastroduodenoscopy and Bone Marrow Biopsy in Staging of Ocular Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Type

Heejung Chae, Cheolwon Suh, Dok Hyun Yoon, Jung Yong Hong, Chan-Sik Park, Jooryung Huh, Ho-Seok Sa, Kyoung Won Kim

Blood (2016) 128 (22): 2988.

https://doi.org/10.1182/blood.V128.22.2988.2988

Published: 2016

Journal Articles

R-CVP Chemoimmunotherapy for Limited-Stage Ocular Adnexal MALT Lymphoma with Adverse Factors: A Phase II Study

Sung-Yong Kim, MD, Seok-Goo Cho, Won-Sik Lee, MD, Suk-Woo Yang, MD, Sung Yong Oh, MD, Hee Bae Ahn, MD, Deok-Hwan Yang, Seong Kyu Park, Jee Ho Chang, MD, Hyo Jung Kim, MD PhD, Min Joung Lee, Jae Wook Yang

Blood (2016) 128 (22): 2981.

https://doi.org/10.1182/blood.V128.22.2981.2981

Published: 2016

Journal Articles

Clinical Features and Outcomes of Plasmacytoma in the United States: Analysis Using the National Cancer Data Base

Gaurav Goyal, MBBS, Wilson I Gonsalves, MD, Ronald S. Go, MD, Shaji Kumar, MD

Blood (2016) 128 (22): 3249.

https://doi.org/10.1182/blood.V128.22.3249.3249

Published: 2016

Journal Articles

Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis for High-Risk DLBCL. -Final Analysis from a Nordic Phase II Study (the CHIC trial)

Blood (2016) 128 (22): 1854.

https://doi.org/10.1182/blood.V128.22.1854.1854

Published: 2016

Journal Articles

Addition of Intermediate-Dose Methotrexate Is Beneficial in Terms of Both Progression-Free Survival and Overall Survival for Patients with Diffuse Large B Cell Lymphoma Receiving Either R-CHOP or CHOP

Eldad J. Dann, MD, Neta Goldschmidt, MD, Vered Heffes, MD, Tanya Mashiach, MSc, Moshe E. Gatt, MD, Netanel A Horowitz, MD

Blood (2016) 128 (22): 1877.

https://doi.org/10.1182/blood.V128.22.1877.1877

Published: 2016

Journal Articles

EZH2 Upregulation Is Associated with Unfavorable Prognosis in Diffuse Large B-Cell Lymphoma through Potential RUNX3 Downregulation

Denise Peker, MD, Samara Roman-Holba, Yuri Kwon, Jennifer Gordetsky, Amitkumar Mehta, MD, Andres Forero, Luciano J. Costa, MD PhD, Vishnu Reddy, MD, Yang Yang, Balabhadrapatruni VSK Chakravarthi, Sooryanarayana Varambally, PhD

Blood (2016) 128 (22): 5301.

https://doi.org/10.1182/blood.V128.22.5301.5301

Published: 2016

Journal Articles

Rivaroxaban for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation and Active Cancer

Eva Simona Laube, MD, Anthony Yu, MD, Dipti Gupta, MD MPH, Yimei Miao, BS, Patrick Samedy, MS, Jonathan Wills, BA, Stephen J. Harnicar, PharmD, BCOP, BCPS, Gerald A. Soff, MD, Simon Mantha, MD MPH

Blood (2016) 128 (22): 2621.

https://doi.org/10.1182/blood.V128.22.2621.2621

Published: 2016

NARROW

Combined Modality Low-Dose Radiation Therapy (2 Gy x 2) and Single-Agent Rituximab Immunotherapy in the Treatment of Indolent Non-Hodgkin Lymphoma

Primary Ocular Lymphoma: A SEER Database Analysis of Patterns of Involvement and Outcomes

Omission of Staging Bone Marrow Biopsy Does Not Affect Outcomes in Patients with Stage I Extranodal Marginal Zone Lymphoma (EMZL) Treated with Radiation Therapy

Non-Diffuse Large B-Cell Primary Central Nervous System Lymphoma

Disease Characteristics and Treatment of Adult Langerhans Cell Histiocytosis: A Single Center Experience

Genetic Landscape of Ocular Adnexa Extranodal Marginal Zone Lymphoma

Prophylaxis with Intrathecal Chemotherapy and High Dose Methotrexate in Patients with Diffuse Large B Cell Lymphoma at High Risk for Central Nervous System Relapse: A Single Centre Experience

Concomitant Use of Blinatumomab and Donor Lymphocyte Infusion for Post-Transplant Relapsed CD19 Positive Acute Lymphoblastic Leukemia: Systematic Review

Incidence and Risk Factors of Central Nervous System Relapse in Localized Extranodal NK/T-Cell Lymphoma, Nasal Type: An Analysis of Nkea Study

Anaplastic Myeloma Arising from Myeloma: Successful Management of Two Diseases in an Individual

Efficacy of Radiation Treatement in Ocular Adnexa Mucosa-Associated Lymphoid Tissue Lymphoma: A Retrospective Evaluation in a Single Center Experience

Rituximab-Bendamustine in First Line Treatment of Patients with Follicular Lymphoma. Results of Prospective Multicenter Study

Curative radiation for orbital MZL: how much?

Limited Role of Workup Including PET-CT, Esophagogastroduodenoscopy and Bone Marrow Biopsy in Staging of Ocular Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Type

R-CVP Chemoimmunotherapy for Limited-Stage Ocular Adnexal MALT Lymphoma with Adverse Factors: A Phase II Study

Clinical Features and Outcomes of Plasmacytoma in the United States: Analysis Using the National Cancer Data Base

Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis for High-Risk DLBCL. -Final Analysis from a Nordic Phase II Study (the CHIC trial)

Addition of Intermediate-Dose Methotrexate Is Beneficial in Terms of Both Progression-Free Survival and Overall Survival for Patients with Diffuse Large B Cell Lymphoma Receiving Either R-CHOP or CHOP

EZH2 Upregulation Is Associated with Unfavorable Prognosis in Diffuse Large B-Cell Lymphoma through Potential RUNX3 Downregulation

Rivaroxaban for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation and Active Cancer

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only